Capecitabine
Click to View Image
C15H22FN3O6 359.35

Carbamic acid, [1-(5-deoxy--d-ribofuranosyl)-5-fluoro-1,2-dihydro-2-oxo-4-pyrimidinyl]-, pentyl ester.
Pentyl 1-(5-deoxy--d-ribofuranosyl)-5-fluoro-1,2-dihydro-2-oxo-4-pyrimidinecarbamate [154361-50-9].
» Capecitabine contains not less than 98.0 percent and not more than 102.0 percent of C15H22FN3O6, calculated on the anhydrous and solvent-free basis.
Packaging and storage— Preserve in tight containers. Store at controlled room temperature.
Identification—
A: Infrared Absorption 197K
Test specimen: 2 mg of sample in 300 mg of potassium bromide.
B: The retention time of the major peak in the chromatogram of the Assay preparation corresponds to that in the chromatogram of the Standard preparation, as obtained in the Assay.
Water, Method Ic 921: not more than 0.3%.
Specific rotation 781S: between +96.0 and +100.0.
Test solution: 10 mg per mL, on the anhydrous and solvent-free basis, in methanol, at 20.
Residue on ignition 281: not more than 0.1%.
Heavy metals, Method II 231: not more than 20 ppm.
Related compounds—
Diluent, Solution A, Solution B, Peak identification solution, and Chromatographic system— Proceed as directed in the Assay.
Standard solution— Use the Standard preparation, prepared as directed in the Assay.
Test solution— Use the Assay preparation, prepared as directed in the Assay.
Procedure— Separately inject equal volumes (about 10 µL) of the Standard solution and the Test solution into the chromatograph, record the chromatograms, and measure the peak responses. Calculate the percentage of each impurity in the portion of Capecitabine taken by the formula:
100(1/F)(CS / CU)(rI / rS)
in which F is the relative response factor for each impurity obtained from Table 1; CS is the concentration, in mg per mL, of USP Capecitabine RS in the Standard solution; CU is the concentration, in mg per mL, of capecitabine in the Test solution; rI is the peak response for each impurity obtained from the Test solution; and rS is the peak response for capecitabine obtained from the Standard solution. The limits are given in Table 1.
Table 1
Compound Relative
Retention
Time
Relative
Response
Factor (F)
Limit (%)
Capecitabine related compound A 0.18 1.05 0.3
Capecitabine related compound B 0.19 0.81 0.3
2¢,3¢-Di-O-acetyl-5¢-deoxy-5-fluorocytidine 0.36 0.89 0.1
5¢-Deoxy-5-fluoro-N4-(2-methyl-1-butyloxycarbonyl)cytidine + 5¢-Deoxy-5-fluoro-N4-(3-methyl-1-butyloxycarbonyl)cytidine 0.95 1.01 0.5
Capecitabine 1.00 1.00
[1-[5-Deoxy-3-O-(5-deoxy--d-ribofuranosyl)--d-ribofuranosyl]-5-fluoro-2-oxo-1,2-dihydropyrimidin-4-yl]-carbamic acid pentyl ester 1.06 1.00 0.3
[1-[5-Deoxy-2-O-(5-deoxy--d-ribofuranosyl)--d-ribofuranosyl]-5-fluoro-2-oxo-1,2-dihydropyrimidin-4-yl]-carbamic acid pentyl ester 1.09 1.00 0.2
Capecitabine related compound C 1.11 0.91 0.3
[1-[5-Deoxy-3-O-(5-deoxy--d-ribofuranosyl)--d-ribofuranosyl]-5-fluoro-2-oxo-1,2-dihydropyrimidin-4-yl]-carbamic acid pentyl ester 1.20 1.00 0.3
2¢,3¢-Di-O-acetyl-5¢-deoxy-5-fluoro-N4-(pentyloxycarbonyl)cytidine 1.37 0.85 0.1
Individual unspecified impurity 1.00 0.1
Total unspecified impurities 0.5
Total impurities 1.5
Assay—
Diluent— Prepare a mixture of water, methanol, and acetonitrile (60:35:5).
Diluted acetic acid— Prepare a 0.1% (v/v) mixture of acetic acid in water.
Solution A— Prepare a mixture of Diluted acetic acid, methanol, and acetonitrile (60:35:5).
Solution B— Prepare a mixture of methanol, Diluted acetic acid, and acetonitrile (80:15:5).
Standard preparation— Dissolve an accurately weighed quantity of USP Capecitabine RS in Diluent, and sonicate if necessary, to obtain a solution having a known concentration of about 0.6 mg per mL.
Peak identification solution— Dissolve suitable quantities of USP Capecitabine RS, USP Capecitabine Related Compound A RS, USP Capecitabine Related Compound B RS, and USP Capecitabine Related Compound C RS in Diluent, and sonicate if necessary, to obtain a solution having known concentrations of about 0.06 mg of each per mL. Quantitatively dilute this solution with Diluent to obtain a solution having known concentrations of about 0.6 µg of each per mL.
Assay preparation— Dissolve an accurately weighed quantity of Capecitabine in Diluent, and sonicate if necessary, to obtain a solution having a known concentration of about 0.6 mg per mL.
Chromatographic system (see Chromatography 621)— The liquid chromatograph is equipped with a 250-nm detector, a refrigerated autosampler at 5, and a 4.6-mm × 25-cm column that contains 5-µm packing L1. The flow rate is about 1 mL per minute. The column temperature is maintained at 40. The chromatograph is programmed as follows.
Time
(minutes)
Solution A
(%)
Solution B
(%)
Elution
0–5 100 0 isocratic
5–20 100®49 0®51 linear gradient
20–30 49 51 isocratic
30–31 49®100 51®0 linear gradient
31–40 100 0 equilibration
Chromatograph the Diluent, followed by the Peak identification solution, and record the peak responses as directed for Procedure: the resolution, R, between capecitabine related compound A and capecitabine related compound B is not less than 1.0. Chromatograph the Standard preparation, and record the peak responses as directed for Procedure: the tailing factor of the capecitabine peak is not greater than 1.5, and the relative standard deviation for replicate injections of the capecitabine peak is not more than 2.0%. [note—For the purpose of peak identification, the approximate relative retention times are given in Table 1. The relative retention times are measured with respect to capecitabine.]
Procedure— Separately inject equal volumes (about 10 µL) of the Standard preparation and the Assay preparation into the chromatograph, record the chromatograms, and measure the responses for the capecitabine peaks. Calculate the quantity, in percentage, of C15H22FN3O6 in the portion of Capecitabine taken by the formula:
100(CS / CU)(rU / rS)
in which CS is the concentration, in mg per mL, of USP Capecitabine RS in the Standard preparation; CU is the concentration, in mg per mL, of capecitabine in the Assay preparation; and rU and rS are the peak responses obtained from the Assay preparation and the Standard preparation, respectively.
Auxiliary Information— Please check for your question in the FAQs before contacting USP.
Topic/Question Contact Expert Committee
Monograph Feiwen Mao, M.S.
Scientist
1-301-816-8320
(MDOOD05) Monograph Development-Ophthalmics Oncologics and Dermatologicals
Reference Standards Lili Wang, Technical Services Scientist
1-301-816-8129
RSTech@usp.org
USP32–NF27 Page 1774
Pharmacopeial Forum: Volume No. 32(4) Page 1052
Chromatographic Column—
Chromatographic columns text is not derived from, and not part of, USP 32 or NF 27.